Synexus has agreed to acquire Leipzig based ClinPharm and will complete the acquisition in January 2010. This deal will increase the number of Synexus’ Dedicated Research Centres to 26 in nine countries, thus significantly strengthening its European reach.
While the company has a network of research centres in Central and Eastern Europe, this acquisition will add eight research centres in Germany.
It will strengthen Synexus’ Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria with additional sites in Austria and Ukraine, enhancing its platform in an area of significant importance to its clients. Synexus now has research centres in Western, Central and Eastern Europe, South Africa and Asia.
Michael Fort, chief executive of Synexus, said: “The Synexus concept has been proven. We made, what were perceived to be, bold statements about our capabilities. Our work with some of the world’s leading pharma companies has, however, now convinced the market that we do represent the new way of finding patients and running clinical trials at Dedicated Research Centres. In order to keep pace with the market’s demands it is necessary for us to increase our infrastructure and patient reach. ClinPharm provided the ideal opportunity as they have considerable presence in Western, Central and Eastern Europe and also understand the way we work.”
The deal will be finalised in January 2010 after ClinPharm’s year end. ClinPharm’s founding CEO, Hans-Detlev Stahl, joins Synexus as European medical director.
Dr Stahl commented: “It was a natural fit to team up with Synexus.
“We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma.”
Dr Helena Sigal, currently ClinPharm’s director of operations, will become Synexus’ country manager in Germany. The Austrian and Ukrainian clinics will join Synexus’ existing CEE region reporting to Dr Christian Tueni, CEE regional director. Both Drs Sigal and Tueni will report to Jane Restorick, Snr VP International Operations.